In the Administration section, code table 3E0, Introduction, Circulatory body system, a new qualifier value, Y Hyperthermic, has been created for the body part value, M Peritoneal Cavity for the antineoplastic substance. This change enables the capture of administration of hyperthermic intraperitoneal chemotherapy (HIPEC).
|M Peritoneal Cavity||3 Percutaneous||0 Antineoplastic||Y Hyperthermic|
Hyperthermic intraperitoneal chemotherapy (HIPEC) combines surgery with chemotherapy for the treatment of cancers in the abdomen. It is administered at the end of cytoreductive surgery, delivering chemotherapy directly into the abdominal cavity after the visible tumors are removed. The hyperthermia enhances absorption of chemotherapy into tumor cells and continues for approximately 90 to 120 minutes. The solution is then removed, and the incision closed. The purpose of the procedure is to increase the temperature inside the abdominal cavity, which helps to destroy cancer cells. The source of the heat is the infusion.
A patient with adenocarcinoma of the appendix with peritoneal metastasis presented for scheduled hyperthermic intraperitoneal chemotherapy (HIPEC). The patient underwent cytoreductive surgery, along with removal of additional pelvic and abdominal organs. Inflow and outflow cannulas were placed, and the patient was given mitomycin in the perfusion circuit for a total of two hours of hyperthermic intraperitoneal chemotherapy. What is the correct code assignment for hyperthermic intraperitoneal chemotherapy?